You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma

Article info

Article menu

Download PDFPDF

Poster Presentation
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Free

Authors

Citation

Hurwitz H, Crocenzi T, Lohr J, et al
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Journal for ImmunoTherapy of Cancer 2014;2:P86. doi: 10.1186/2051-1426-2-S3-P86

Publication history

  • First published November 6, 2014.
Online issue publication 
March 11, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2014